Localization of gene for human syndecan, an integral membrane proteoglycan and a matrix receptor, to chromosome 2

Allopurinol Protective Effect of Renal Ischemia by Downregulating TNF-α, IL-1β, and IL-6 Response

Allopurinol is a well-known antioxidant that protects tissue against ischemia and reperfusion injury, blocking purine catabolism, and possibly reducing TNF-α and other cytokines. It also plays a significant role in reducing the inflammatory processes by inhibiting chemotaxis and other inflammatory mediators. The objective of this study was to define the role of allopurinol regarding kidney ischemic injury particularly as to its effect on inflammatory molecules such as TNF-α, IL-1β, and IL-6 response. One hundred and twenty five rats were subjected to warm renal ischemia. Five more animals were included as sham. Animal survival and plasma levels of lipid peroxidation, myeloperoxidase, lactate dehydrogenase, glutathione, urea, creatinine, and cytokines were determined. Inflammatory parameters (TNF-α, IL-1β, and IL-6) were measured in all groups by quantitative immunosorbent assay. Further, immunohistological and histopathological studies were carried out on animals treated prior to, or following reperfusion with 10 and 50 mg/kg of Allopurinol. The statistical analysis included ANOVA and Fisher test as well as χ² test. Significance was reached at a p < 0.05. The results of this study indicated that Allopurinol protected against kidney ischemia-reperfusion injury since significantly better results of survival, biochemical analysis, and histopathological testing were observed in treated animals as compared to ischemic controls. In conclusion, Allopurinol protected ischemic kidneys through a mechanism associated with downregulation of TNF-α, IL-1 β, and IL-6, in addition to other well-known effects such as decreased lipid peroxidation and neutrophil activity. It also increased antioxidant capacity and diminished endogenous peroxidase stain in renal ischemic tissue. Therefore, this experiment showed an effectiveness of allopurinol protection against proteomic and morphological damage.

Syndecan-1 - A new piece in B-cell puzzle

Syndecans are transmembrane proteoglycans, with core proteins mainly decorated with heparan sulfate chains. Syndecan-1 is expressed in a tissue-, cell-and differentiation-specific manner. Its extra-cellular domain can bind via HS chains to matrix elements, to growth factors (especially "heparin-binding" proteins) and to certain biological agents. The ectodomain released by proteolysis can also be functionally active. The cytoplasmic domain can take part in signaling processes as well as in modifying cell shape. In hematopoietic cells syndecan-1 is expressed in normal pre-B-cells and plasma cells, as well as in plasmocytoid and lymphoplasmocytoid malignancies. According to our study syndecan-1 is expressed in B-CLL cells both in tissue environment and in circulation.

Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma

PURPOSE

Amplification of the MYCN oncogene at chromosome 2p24-25 identifies an aggressive subtype of human neuroblastoma with a poor clinical outcome. Differences in amplicon structure and coamplification of genes telomeric and centromeric to the MYCN oncogene have previously been described. A relevant role of gene coamplification for neuroblastoma pathogenesis remains elusive.

PATIENTS AND METHODS

We analyzed 98 primary neuroblastoma tumors with MYCN amplification for coamplification of seven additional genes at chromosome 2p24-25 (DDX1, NAG, NSE1, LPIN1, EST-AA581763, SMC6, and SDC1). Two semiquantitative multiplex polymerase chain reactions were used to obtain the amplification status of the target genes in relation to a reference gene on chromosome 2q (Inhibin-beta-b). Furthermore, mRNA expression pattern of coamplified genes in a subset of tumors was analyzed.

RESULTS

Our results show that the frequency of gene coamplification on 2p24-25 in neuroblastoma is correlated directly to the physical distance to MYCN. Coamplification is correlated to an upregulated gene expression for DDX1 and NAG. Coamplification of the DDX1 gene within 400kb telomeric to MYCN identifies a subgroup of advanced stage neuroblastoma tumors with a more favorable outcome (P =.027, log-rank test). A high expression level of DDX1 is associated with a trend towards a better survival probability (P =.058, log-rank test).

CONCLUSION

Our results indicate that DDX1 coamplification correlates with a better prognosis and improved patient survival in MYCN-amplified neurobastoma.

Expression of syndecan gene is induced early, is transient, and correlates with changes in mesenchymal cell proliferation during tooth organogenesis

Syndecan is an integral cell surface proteoglycan which contains an extracellular matrix-binding domain and a cytoskeleton-associated domain and may therefore transfer changes in the extracellular environment to cellular behavior. Changes in syndecan gene expression during embryonic and early postnatal mouse tooth development were analyzed by in situ hybridization and compared with the distribution of syndecan core protein and cell proliferation studied by immunohistochemistry. Syndecan RNA became accumulated in the condensing mesenchymal cells around the invaginating epithelial tooth bud during early development, and this accumulation became more intense when morphogenesis advanced to the cap stage. During the bell stage, when the cuspal pattern of the tooth is established, syndecan transcripts were lost, and RNA was not detected in the terminally differentiated or postmitotic odontoblasts. In the epithelium, syndecan RNA was intensely expressed in the invaginating epithelial bud, but the expression was reduced during the cap and bell stages. However, local stimulation in syndecan gene expression was observed in the epithelial preameloblasts immediately preceding their terminal differentiation into ameloblasts, which was accompanied by a complete loss of transcripts. There was a close correlation between the changes in syndecan transcripts and the distribution of syndecan core protein. Furthermore, analysis of cell proliferation by immunohistochemical detection of BrdU incorporation revealed that in the mesenchyme, but not in the epithelium, syndecan was intensely expressed by proliferating cells. The analysis of mRNA by Northern blot indicated that the transcripts in mesenchymal and epithelial cells were of similar size. In the slot-blot analysis the changes in syndecan transcripts correlated with the overall changes observed in the in situ hybridization analysis. The role of tissue interactions in the regulation of the syndecan gene was studied by using tissue recombination cultures of separated epithelial and mesenchymal components of the early tooth germ. The in situ hybridization and Northern blot analysis of these explants showed that the expression was increased in the mesenchyme cultured in contact with the epithelium. Our results indicate that syndecan gene expression in the embryonic tooth mesenchyme is induced by epithelial-mesenchymal interactions and thereafter expressed stage-dependently and transiently by the differentiating cells during organogenesis. The association of syndecan expression with mesenchymal cell proliferation raises the possibility that, in addition to behaving as a matrix receptor, syndecan may have a role in controlling growth and that syndecan may have different functions in epithelial and mesenchymal cells.